Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

Inclusion Criteria: * Newly diagnosed with acute myeloid leukemia (AML) in accordance with the 2018 WHO Classification and Diagnostic Criteria for Acute Leukemias; received 1-2 courses of conventional chemotherapy, achieved remission, and are undergoing routine consolidation therapy. * Aged 18 to 70 years. * Receiving a maintenance therapy regimen without hormonal agents. * Leukocyte and lymphocyte counts have basically returned to the normal range. * Patients judged by the investigator to have an expected survival of at least 12 months after achieving remission. * Patients who voluntarily participate in this study and sign the informed consent form. Exclusion Criteria： * Patients who still require hormonal maintenance therapy after achieving remission. * Patients with a concomitant history of other malignant tumors or a history of uncontrolled malignant tumors. * Having participated in other clinical trials within 1 month prior to screening. * Complicated with uncontrolled cerebrovascular diseases, coagulation disorders, connective tissue diseases and other similar conditions. * Having other uncontrolled diseases that the investigator deems unfit for enrollment. * Patients with psychiatric disorders or those known/suspected to be unable to fully comply with the study protocol. * Pregnant or lactating women. * HIV-infected individuals. * Other conditions that the investigator deems may prevent the subject from completing the study or pose a significant safety risk to the subject. Withdrawal Criteria： * Judged by the investigator to be in the best interest of the subject. * Disease progression or initiation of other anti-leukemia therapy. * The subject requests to withdraw from the study for any reason at any time. * Lost to follow-up. * Death. * Occurrence of severe chemotherapy-induced toxic reactions, or chemotherapy delay of more than 4 weeks due to adverse reactions. * Cardiac toxicity: Left Ventricular Ejection Fraction (LVEF) ≤ 50% or a decrease of \> 10%; or QTc prolongation meeting the following criteria: ① QTc \> 500 ms; ② QTc \> 530 ms in patients with bundle branch block. * Hepatic toxicity: Persistent elevation of alanine transaminase (ALT) and/or aspartate transaminase (AST) to more than 2 times the upper limit of normal (ULN), with no response to hepatoprotective treatment.